Diligence memo · auto-generated · as of July 2, 2026

Jivana Biotechnology Inc

Jivana Biotechnology Inc looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Jivana Biotechnology Inc operates in Biotechnology, based in Oak Park.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Jivana Biotechnology Inc has raised $2.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $1.0M on 2015-12-01.

Most recent recorded round closed around 2016-10-10.

Valuation (modeled)modeled

Provath models Jivana Biotechnology Inc at approximately $55M (range $533K–$626M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.61× the median modeled value of Pre-Seed Biotechnology companies in 2016–2018 (152 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.

Financing rhythm & timingmixed

Historic cadence: a new round about every 4 months.

Last raise 9.7 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 28% of Biotechnology peers (4293 compared).

Modeled value ranks above 48% of those peers.

Closest niche peers: New Vital Signs, Inc., Cerebral Magnetics INC, NutriBand Inc., AnTolRx, Inc., US Biologic, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.